UPDATE: Credit Suisse Initiates Outperform, $7 PT on XenoPort; Valuation Trumps Fundamental Concerns
Credit Suisse initiates its coverage on XenoPort (NASDAQ: XNPT) with an Outperform rating and a price target of $7 per share.
Credit Suisse says, "Despite a number of fundamental concerns, at its current valuation ($219mn market cap/$165mn y/e EV) and with low expectations for its marketed products and pipeline, we think relatively little has to go right for the stock price to appreciate. Specifically we see 3 main upside optionality triggers which are not factored into our numbers/valuation (a) delivery of greater Regnite/Horizant revenues - either via high end-user sales and/or US re-partnering (b) monetization of clinical assets, in particular XP23829 or (c) the company seeks strategic alternatives."
XNPT closed at $6.07 on Wednesday.
Latest Ratings for XNPT
|Apr 2014||Jefferies||Initiates Coverage on||Buy|
|Jun 2013||Morgan Stanley||Downgrades||Equal-weight||Underweight|
|May 2013||Deutsche Bank||Maintains||Buy||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.